Showing results (711-720 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|June 10, 2026
HIV-1 subtype diversity in EuropeMiłosz Parczewski, Karol Serwin, Dimitros Paraskevis, et al.
The Lancet. HIV|June 17, 2023
HIV prevalence, risk behaviour, and treatment and prevention cascade outcomes among cisgender men, transgender women, and transgender men who sell sex in Zimbabwe: a cross-sectional analysis of programme dataMariëlle Kloek, Sungai T Chabata, Laura van Noord, et al.
The Lancet. HIV|June 11, 2026
Guidance on the clinical management of HIV-1 persistent low-level viraemia on antiretroviral treatment: a scoping review and an international Delphi consensusTommaso Clemente, Arjen J Stam, Olof Elvstam, et al.
The Lancet. HIV|June 12, 2026
Epidemiological and economic effect of preference-driven HIV pre-exposure prophylaxis implementation for men who have sex with men and transgender women across 16 countries and territories in the Asia-Pacific region: a modelling studyShihao He, Warittha Tieosapjaroen, Xiaoyi Cui, et al.
The Lancet. HIV|April 30, 2026
Trends in incidence of HIV and other sexually transmissible infections among transgender people in Australia: a retrospective 10-year national clinical cohort studyDenton Callander, Teddy Cook, Jason Asselin, et al.
The Lancet. HIV|May 10, 2026
Global mental health disparities among transgender women and transfeminine people living with HIV: a systematic review and meta-analysis of 63 studiesDavid R A Coelho, Maria L R Defante, Rômulo da Silva Sanglard, et al.
The Lancet. HIV|April 11, 2026
Targeted universalism for long-acting PrEP: an urgent need to avoid risk targeting and build population-level impactLaura K Beres, Sheree R Schwartz, Ronald Olum, et al.
The Lancet. HIV|March 30, 2026
Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort studyY Joseph Hwang, Catherine R Lesko, Todd T Brown, et al.
The Lancet. HIV|February 27, 2026
Post-mortem characterisation of HIV-associated under-5 deaths in the CHAMPS network: population-based mortality surveillanceInacio Mandomando, Zachary J Madewell, Portia C Mutevedzi, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Pageof 79